S
SELLAS Life Sciences Group, Inc.
SLS · NASDAQ · Healthcare · 2.4B
Closing price
$11.65
+3.46% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
17.9×
Enterprise value / EBITDAEV/EBITDA
-44.7×
Free cash flow yieldFCF yield
-2.2%
Return on equityROE
-37.9%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
2.6×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.